Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Georgetown Lombardi Comprehensive Cancer Center

3800 Reservoir Road, N.W., Washington D.C. 20057

Georgetown Lombardi Comprehensive Cancer Center is designated by the National Cancer Institute as a comprehensive cancer center — the only cancer center of its kind in the Washington, DC area. A part of Georgetown University Medical Center and MedStar Georgetown University Hospital, Georgetown Lombardi seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Connect with Georgetown Lombardi on Facebook (Facebook.com/GeorgetownLombardi) and Twitter (@LombardiCancer).

Website: Georgetown Lombardi Comprehensive Cancer Center

Contact:
Lombardi CancerLine
202-444-4000

Trials at this location:

GI16-263

Study Title: A phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma with pembrolizumab and Sylatron (peginterferon alfa-2b) HCRN GI16-263

Status: Open to Accrual
Read More

GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Status: Open to Accrual
Read More

GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status: Open to Accrual
Read More

BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status: Open to Accrual
Read More

TBCRC-035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

Status: Open to Accrual
Read More